Tenaya Therapeutics, Inc. TNYA
We take great care to ensure that the data presented and summarized in this overview for Tenaya Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TNYA
View all-
Column Group LLC San Francisco, CA9.4MShares$4.23 Million24.12% of portfolio
-
Casdin Capital, LLC New York, NY6.73MShares$3.03 Million0.83% of portfolio
-
Jpmorgan Chase & CO New York, NY5.16MShares$2.32 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.07MShares$1.83 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$1.47 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY1.56MShares$700,0000.37% of portfolio
-
Ghost Tree Capital, LLC New York, NY1.5MShares$675,0001.08% of portfolio
-
Morgan Stanley New York, NY1.49MShares$669,7370.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.27MShares$570,9310.0% of portfolio
-
State Street Corp Boston, MA1.1MShares$496,3910.0% of portfolio
Latest Institutional Activity in TNYA
Top Purchases
Top Sells
About TNYA
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Insider Transactions at TNYA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 10
2025
|
Tomohiro Higa SVP, Finance |
SELL
Open market or private sale
|
Direct |
2,482
-0.82%
|
$0
$0.54 P/Share
|
|
Mar 10
2025
|
Faraz Ali Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,741
-1.49%
|
$0
$0.54 P/Share
|
|
Mar 10
2025
|
Whittemore Tingley Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,398
-1.37%
|
$0
$0.54 P/Share
|
|
Mar 05
2025
|
Column Group Iii Gp, LP |
BUY
Open market or private purchase
|
Indirect |
35,714,284
+42.0%
|
$0
$0.7 P/Share
|
|
Mar 05
2025
|
David V Goeddel |
BUY
Open market or private purchase
|
Indirect |
35,714,284
+42.0%
|
$0
$0.7 P/Share
|
|
Feb 06
2025
|
Faraz Ali Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
141,924
+18.05%
|
-
|
|
Jan 24
2025
|
Whittemore Tingley Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,676
+18.21%
|
-
|
|
Nov 18
2024
|
Chihiro Saito SVP, Accounting and Fin. Ops. |
SELL
Open market or private sale
|
Direct |
2,258
-3.57%
|
$4,516
$2.12 P/Share
|
|
Aug 16
2024
|
Chihiro Saito SVP, Accounting and Fin. Ops. |
SELL
Open market or private sale
|
Direct |
2,363
-1.22%
|
$4,726
$2.89 P/Share
|
|
Aug 16
2024
|
Faraz Ali Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,748
-2.49%
|
$19,496
$2.89 P/Share
|
|
Aug 16
2024
|
Whittemore Tingley Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,428
-3.28%
|
$14,856
$2.89 P/Share
|
|
Aug 15
2024
|
Chihiro Saito SVP, Accounting and Fin. Ops. |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+27.59%
|
-
|
|
Mar 05
2024
|
Timothy Hoey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,300
-1.33%
|
$23,100
$7.0 P/Share
|
|
Feb 23
2024
|
Leone D Patterson Chief Fin. and Bus. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+26.77%
|
-
|
|
Feb 23
2024
|
Whittemore Tingley Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+24.38%
|
-
|
|
Feb 23
2024
|
Timothy Hoey Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+4.79%
|
-
|
|
Feb 23
2024
|
Faraz Ali Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+30.03%
|
-
|
|
Feb 20
2024
|
Timothy Hoey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,569
-1.35%
|
$32,845
$5.74 P/Share
|
|
Feb 16
2024
|
Whittemore Tingley Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,500
-8.12%
|
$32,500
$5.86 P/Share
|
|
Feb 16
2024
|
Timothy Hoey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,681
-1.89%
|
$23,405
$5.86 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 71.4M shares |
|---|---|
| Grant, award, or other acquisition | 239K shares |
| Open market or private sale | 41.4K shares |
|---|